Pentamidine intravenous
Alternative Names: OCZ 103 OS; Pentamidine bis (2-hydroxyethanesulfonate); Pentamidine isethionateLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Unknown
- Developer Oncozyme Pharma
- Class Antifungals; Antineoplastics; Antiprotozoals; Benzamidines; Sulfonic acids
- Mechanism of Action Endoexonuclease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 28 Jun 2013 Oncozyme Pharma completes a phase IIa trial for Non-small cell lung cancer (first-line combination therapy, late-stage disease) in Poland (EudraCT2012-001812-50)
- 01 May 2013 Oncozyme Pharma completes enrolment in its phase IIa trial for Non-small cell lung cancer (first-line combination therapy, late-stage disease) in Poland (EudraCT2012-001812-50)
- 18 Sep 2012 Phase-II clinical trials in Non-small cell lung cancer (first-line combination therapy, late-stage disease) in Poland (IV)